Pine Haven Investment Counsel Inc Boosts Stock Position in IDEXX Laboratories, Inc. $IDXX

Pine Haven Investment Counsel Inc lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,205 shares of the company’s stock after buying an additional 50 shares during the period. Pine Haven Investment Counsel Inc’s holdings in IDEXX Laboratories were worth $646,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of IDXX. Waverly Advisors LLC lifted its holdings in shares of IDEXX Laboratories by 20.4% in the 4th quarter. Waverly Advisors LLC now owns 660 shares of the company’s stock worth $273,000 after acquiring an additional 112 shares during the last quarter. Vise Technologies Inc. grew its stake in shares of IDEXX Laboratories by 20.3% during the fourth quarter. Vise Technologies Inc. now owns 633 shares of the company’s stock valued at $262,000 after buying an additional 107 shares during the last quarter. Forum Financial Management LP increased its holdings in shares of IDEXX Laboratories by 4.9% in the fourth quarter. Forum Financial Management LP now owns 621 shares of the company’s stock worth $257,000 after buying an additional 29 shares during the period. B. Riley Wealth Advisors Inc. lifted its stake in shares of IDEXX Laboratories by 97.0% in the 4th quarter. B. Riley Wealth Advisors Inc. now owns 1,838 shares of the company’s stock valued at $760,000 after acquiring an additional 905 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in IDEXX Laboratories during the 4th quarter worth approximately $38,818,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

IDXX stock opened at $648.38 on Wednesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $688.12. The company has a market cap of $51.87 billion, a P/E ratio of 53.99, a price-to-earnings-growth ratio of 4.17 and a beta of 1.56. The stock’s fifty day moving average price is $619.13 and its 200-day moving average price is $523.97.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the previous year, the company posted $2.44 EPS. The business’s quarterly revenue was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 2,187 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the completion of the transaction, the director owned 262 shares in the company, valued at $169,600.46. This trade represents a 89.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Michael G. Erickson sold 406 shares of the stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $649.96, for a total transaction of $263,883.76. Following the completion of the transaction, the executive vice president directly owned 11,287 shares of the company’s stock, valued at approximately $7,336,098.52. The trade was a 3.47% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 54,057 shares of company stock worth $34,293,468. Insiders own 0.98% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. JPMorgan Chase & Co. increased their price objective on IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a research note on Monday, August 4th. BTIG Research raised their price target on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the stock a “buy” rating in a report on Tuesday, August 5th. Stifel Nicolaus set a $640.00 price objective on shares of IDEXX Laboratories in a research report on Monday, August 4th. Leerink Partners boosted their price target on IDEXX Laboratories from $580.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. Finally, Jefferies Financial Group began coverage on IDEXX Laboratories in a report on Tuesday, July 1st. They issued a “buy” rating and a $625.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $649.44.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.